Episode Details

Back to Episodes

Can High-Dose Vitamin B3 Protect the Optic Nerve? A New Glaucoma Trial Will Test 3 Grams a Day

Published 2 months ago
Description

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/can-high-dose-vitamin-b3-protect-the-optic-nerve-a-new-glaucoma-trial-will-test-3-grams-a-day

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

Can High-Dose Vitamin B3 Protect the Optic Nerve? A New Glaucoma Trial Will Test 3 Grams a Day Research updated September 13, 2026 Introduction Glaucoma treatment has traditionally focused on one target: lowering intraocular pressure. That strategy clearly helps, but it does not eliminate risk. Some patients continue to lose retinal ganglion cells and visual-field sensitivity even when their eye pressure appears well controlled. The NADIR trial—NCT07808333—is designed to test a different strategy. It will add high-dose oral nicotinamide, the non-flushing form of vitamin B3, to standard glaucoma treatment and measure whether the inner retinal layers thin more slowly. The central biological idea is straightforward: > Retinal ganglion cells may become metabolically fragile before they die. If nicotinamide raises cellular nicotinamide adenine dinucleotide availability, it might help stressed but living cells withstand glaucoma-related injury. That hypothesis is supported by striking animal research, early human electrophysiology studies, and a plausible link between aging, mitochondrial dysfunction, impaired axonal transport, and retinal ganglion-cell degeneration. But the human evidence remains preliminary—and 3 grams daily is a pharmacological dose, not an ordinary nutritional supplement dose. My overall assessment is that nicotinamide is one of the most credible current candidates for pressure-independent glaucoma neuroprotection, but it is not yet proven to slow glaucoma progression in humans. --- The NADIR Trial: What Is Actually Being Tested? As of September 13, 2026, NADIR is listed as not yet recruiting. It is a single-center University of Chicago study expected to begin enrollment in June 2027. The registry describes it as a Phase 2 study, while the protocol title calls it a Phase 2a trial. () Trial summary For the full table, please open this article on visualfieldtest.com. The trial is important because it is not asking whether nicotinamide lowers eye pressure. It is asking whether it protects retinal tissue despite ongoing standard pressure-lowering treatment. Who can participate? NADIR is designed for adults with mild to moderate primary open-angle glaucoma, not advanced disease. Key inclusion requirements include: Age 40 to 80 years Primary open-angle glaucoma in at least one eye Study-eye visual-field mean deviation between −2.0 and −12.0 decibels At least one reliable Humphrey 24-2 visual-field test Fixation losses of 33% or less False-positive responses of 15% or less Best-corrected visual acuity of 20/40 or better Structural damage on optical coherence tomography and/or a reproducible glaucomatous visual-field defect Macular ganglion cell-inner plexiform layer and retinal nerve fiber layer thickness above the device’s measurement floor Stable pressure-lowering therapy for at least four months Screening intraocular pressure of 21 millimeters of mercury or less The visual-field range is strategically chosen. Patients with mean deviation between −2 and −12 decibels still have enough surviving retinal tissue for a protective treatment to be measurable, but they have established disease rather than merely being glaucoma suspects. () Who is excluded? The important exclusions include: Advanced glaucoma with mean deviation worse than −12 decibels Best-corrected v

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us